Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 2/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.38 |
| ▸ | GSK3B | P49841 | 10/20 | 0.37 |
| ▸ | QPCT | Q16769 | 8/20 | 0.37 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.36 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | FLT3 | P36888 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | SYK | P43405 | 4/20 | 0.34 |
| ▸ | HTR6 | P50406 | 1/20 | 0.34 |
| ▸ | FCER2 | P06734 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7664757 | 0.91 | CAMK2D (0.38) | GSK3BQPCT | |
| SCHEMBL7655905 | 0.90 | EGLN1 (0.39) | EGLN1KDR | |
| SCHEMBL7657220 | 0.89 | CAMK2D (0.42) | GSK3BKDR | |
| SCHEMBL7658038 | 0.87 | GSK3B (0.33) | GSK3BQPCTTDP1 | |
| Acetic Acid SCHEMBL7658926 | 0.85 | PDE4B (0.45) | PDE4BPDE4DGSK3BQPCTPRKD1 | |
| SCHEMBL7661618 | 0.85 | PDE4B (0.38) | PDE4BPDE4DGSK3BQPCTPRKD1 | |
| SCHEMBL7660686 | 0.85 | CAMK2D (0.33) | GSK3BKDR | |
| SCHEMBL7654136 | 0.84 | EGLN1 (0.39) | EGLN1 | |
| SCHEMBL7656458 | 0.84 | PDE4B (0.40) | PDE4BPDE4DGSK3BQPCTPRKD1 | |
| Acetic Acid SCHEMBL7664639 | 0.83 | PDE4B (0.39) | PDE4BPDE4DGSK3BQPCTEGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6458792-B1 | MEDICAMENT FOR THE TREATMENT OF INFLAMMATORY, IMMUNOLOGICAL, BRONCHOPULMONARY, CARDIOVASCULAR, ONCOLOGICAL OR CNS-DEGENERATIVE DISORDERS. | ASTRAZENECA AB (SE) | 2002-10-01 | — | — | US | disclosed |